defactinib (VS-6063)

Phase 2

Verastem, Inc. (VSTM)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

19 competitors in Non Small Cell Lung Cancer

Drug Information

Target Indication

Non Small Cell Lung Cancer

Clinical Trial

NCT01951690

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VSTM

Verastem, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

avutometinibPhase 3

Low Grade Serous Ovarian Cancer

avutometinib (VS-6766)Phase 2

Low Grade Ovarian Serous Adenocarcinoma

avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelPhase 2

KRAS Activating Mutation

Avutometinib (VS-6766) + Defactinib (VS-6063)Phase 2

Low Grade Serous Ovarian Cancer

avutometinib (VS-6766) and adagrasibPhase 2

Non Small Cell Lung Cancer

View full pipeline